$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000143853322000051 Filed on October 27, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$55.87M	$53.50M
YoY Change	-2.41%	-21.58%
Cost Of Revenue	$1.728M	$1.675M
YoY Change	-8.86%	5.21%
Gross Profit	$54.14M	$51.82M
YoY Change	-2.19%	-22.22%
Gross Profit Margin	96.91%	96.87%
Selling, General & Admin	$56.60M	$57.52M
YoY Change	57.86%	59.49%
% of Gross Profit	104.54%	111.0%
Research & Development	$57.79M	$59.26M
YoY Change	-6.61%	22.41%
% of Gross Profit	106.73%	114.35%
Depreciation & Amortization	$9.301M	$8.578M
YoY Change	53.74%	8.95%
% of Gross Profit	17.18%	16.55%
Operating Expenses	$121.0M	$116.8M
YoY Change	17.99%	38.24%
Operating Profit	-$66.85M	-$68.13M
YoY Change	41.66%	114.86%
Interest Expense	$219.0K	-$2.892M
YoY Change	-104.53%	-40.97%
% of Operating Profit
Other Income/Expense, Net	$872.0K	-$1.377M
YoY Change	92.07%	-64.56%
Pretax Income	-$65.76M	-$69.51M
YoY Change	27.52%	95.28%
Income Tax	$63.00K	$145.0K
% Of Pretax Income
Net Earnings	-$65.82M	-$69.66M
YoY Change	27.63%	95.45%
Net Earnings / Revenue	-117.82%	-130.21%
Basic Earnings Per Share	-$1.03	-$1.09
Diluted Earnings Per Share	-$1.03	-$1.09
COMMON SHARES
Basic Shares Outstanding	64.17M shares	63.96M shares
Diluted Shares Outstanding		64.03M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$347.2M	$448.1M
YoY Change	-18.86%	-1.04%
Cash & Equivalents	$61.69M	$151.3M
Short-Term Investments	$285.5M	$296.8M
Other Short-Term Assets	$12.62M	$8.549M
YoY Change	95.09%	13.93%
Inventory	$6.922M	$7.297M
Prepaid Expenses
Receivables	$16.65M	$12.70M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$486.4M	$534.8M
YoY Change	-16.54%	-7.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.049M	$9.557M
YoY Change	-18.52%	-16.99%
Goodwill	$900.0K	$900.0K
YoY Change	0.0%	-3.85%
Intangibles	$145.0M	$149.5M
YoY Change	-2.29%
Long-Term Investments
YoY Change
Other Assets	$11.06M	$11.09M
YoY Change	-0.07%	-68.19%
Total Long-Term Assets	$186.1M	$191.4M
YoY Change	-3.95%	-2.36%
TOTAL ASSETS
Total Short-Term Assets	$486.4M	$534.8M
Total Long-Term Assets	$186.1M	$191.4M
Total Assets	$672.6M	$726.2M
YoY Change	-13.4%	-6.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.29M	$14.01M
YoY Change	14.17%	140.31%
Accrued Expenses	$95.74M	$88.38M
YoY Change	27.35%	39.61%
Deferred Revenue	$11.98M	$11.38M
YoY Change	-26.38%	-29.16%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$142.2M	$131.0M
YoY Change	14.57%	15.79%
LONG-TERM LIABILITIES
Long-Term Debt	$375.5M	$375.1M
YoY Change	65.74%	67.69%
Other Long-Term Liabilities	$9.385M	$9.304M
YoY Change	-23.55%	-78.49%
Total Long-Term Liabilities	$9.385M	$9.304M
YoY Change	-23.55%	-78.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$142.2M	$131.0M
Total Long-Term Liabilities	$9.385M	$9.304M
Total Liabilities	$629.7M	$625.5M
YoY Change	32.71%	33.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.014B	-$948.4M
YoY Change	32.41%	32.76%
Common Stock	$6.000K	$6.000K
YoY Change	0.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$42.85M	$100.7M
YoY Change
Total Liabilities & Shareholders Equity	$672.6M	$726.2M
YoY Change	-13.4%	-6.3%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$65.82M	-$69.66M
YoY Change	27.63%	95.45%
Depreciation, Depletion And Amortization	$9.301M	$8.578M
YoY Change	53.74%	8.95%
Cash From Operating Activities	-$54.64M	-$39.53M
YoY Change	103.3%	-223.27%
INVESTING ACTIVITIES
Capital Expenditures	$4.197M	-$7.633M
YoY Change	-180.71%	42.04%
Acquisitions
YoY Change
Other Investing Activities	-$32.50M	$17.71M
YoY Change	-358.58%	-53.26%
Cash From Investing Activities	-$36.70M	$10.08M
YoY Change	-597.98%	-69.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	551.0K	2.278M
YoY Change	-98.34%	-5.63%
NET CHANGE
Cash From Operating Activities	-54.64M	-39.53M
Cash From Investing Activities	-36.70M	10.08M
Cash From Financing Activities	551.0K	2.278M
Net Change In Cash	-90.79M	-27.17M
YoY Change	-762.41%	-140.55%
FREE CASH FLOW
Cash From Operating Activities	-$54.64M	-$39.53M
Capital Expenditures	$4.197M	-$7.633M
Free Cash Flow	-$58.84M	-$31.89M
YoY Change	171.43%	-185.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	TRAVERE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TVTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64173570	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151337000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165753000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	354989000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12670000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15914000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	7297000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7313000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8549000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6718000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	534842000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	582827000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9557000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11106000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21253000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23196000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	149469000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	148435000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11094000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11069000	usd
CY2022Q3	us-gaap	Assets Assets	726215000	usd
CY2021Q4	us-gaap	Assets Assets	776633000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	14010000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15144000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	88383000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75180000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11383000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16268000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7300000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7400000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4233000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3908000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5723000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6188000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	131032000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	124088000	usd
CY2022Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	375117000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	226581000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12919000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	20379000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	68900000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	59700000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28267000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31497000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9304000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12276000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	625539000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	474521000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64150510	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64150510	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62491498	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62491498	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1048767000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1068634000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-948400000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-765966000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	303000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-562000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	100676000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	726215000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	776633000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53496000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68217000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156150000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	170241000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1675000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1592000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5864000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4888000	usd
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	59256000	usd
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	48407000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	175548000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	148160000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	57519000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36065000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	157286000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107808000	usd
CY2022Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3180000	usd
CY2021Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	13864000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	17167000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	23960000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	121630000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4083000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	99928000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	355865000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	284816000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-68134000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31711000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-199715000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-114575000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2101000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	360000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3161000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1757000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2892000	usd
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4899000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8379000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-15072000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-586000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	654000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	102000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-223000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1377000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3885000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12694000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13538000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69511000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35596000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-212409000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128113000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	145000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	405000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-69656000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212659000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64033759	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64033759	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60803045	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60803045	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63604962	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63604962	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59230881	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59230881	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-69656000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212659000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2596000	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	216000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	4083000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	1091000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1211000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-100000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3218000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-714000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68271000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35523000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-211794000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-128141000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	156713000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8464000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6757000	usd
CY2022Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3408000	usd
CY2021Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3605000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	362000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	228000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2596000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	216000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1211000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-100000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-69656000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35639000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	100676000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	307370000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28751000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	21524000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	4354000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	6679000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2428000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1938000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1091000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3218000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-714000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212659000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	100676000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	307370000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212659000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-128518000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	29649000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	22190000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23778000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20567000	usd
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the nine months ended September 30, 2022, these governmental actions and similar actions that may be enacted in the future, and the widespread economic disruption arising from the pandemic, have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan is a novel investigational product candidate and has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerois (FSGS) and immunoglobulin A nephropathy (IgAN) in the U.S. and Europe. Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in rare kidney diseases.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with cerebrotendinous xanthomatosis (CTX), and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS. The Company is no longer pursuing the identification of potential small molecule therapeutics for NGLY1 deficiency.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. </span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Thiola</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Thiola EC</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div>
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	17167000	usd
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	23960000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6449000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5675000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1194000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8356000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2070000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1372000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3658000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5028000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3264000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2577000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	396000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-17006000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2053000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	380000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1562000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2045000	usd
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	-738000	usd
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	5823000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-364000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4325000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	15229000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6233000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8898000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40153000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2119000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-237000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131651000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12085000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	329612000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	376099000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	301104000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	502141000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	161000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4947000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	24199000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14004000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4148000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144993000	usd
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1575000	usd
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1575000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1875000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2065000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	316250000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9882000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	211324000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4354000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6679000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1529000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1275000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	117022000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	198470000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3935000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14416000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	65555000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165753000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151337000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150327000	usd
CY2022Q3	tvtx	Number Of Phase3 Clinical Trials In Process NumberOfPhase3ClinicalTrialsInProcess	3	clinical_trial
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3680000	usd
	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	The Company receives payments from its product sales based on terms that generally are within 30 days of delivery of product to the patient.
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	329600000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	301100000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	354989000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	354989000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q3	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	299378000	usd
CY2022Q3	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	usd
CY2022Q3	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	2625000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	296753000	usd
CY2022Q3	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	59291000	usd
CY2022Q3	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	0	usd
CY2022Q3	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	1055000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	58236000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	358669000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	262345000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	159000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	262186000	usd
CY2021Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	125254000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	0	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	311000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	124943000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	387599000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	470000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	292606000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	3175000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	62383000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	505000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	354989000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3680000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	380690000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	470000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	380690000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	470000	usd
CY2022Q3	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	358700000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	381200000	usd
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q2	tvtx	Lessee Operating Lease Aggregate Liability LesseeOperatingLeaseAggregateLiability	49500000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3700000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1513000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6200000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6386000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6578000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6775000	usd
CY2022Q3	tvtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	11760000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	39212000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6712000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	32500000	usd
CY2022Q3	tvtx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	5820000	usd
CY2022Q3	tvtx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	5427000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21253000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3600000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	552882000	usd
	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2022Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	151337000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	354989000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	506326000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	76200000	usd
CY2022Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	76200000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	165753000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	67100000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	67100000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	67100000	usd
	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue	17167000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	5387000	usd
	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued	2680000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	76200000	usd
CY2022Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3200000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	17200000	usd
CY2021Q3	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	13900000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	24000000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18432000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	306787000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	283557000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	158254000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	136058000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148533000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	147499000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	900000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8069000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6344000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22196000	usd
CY2022Q1	tvtx	Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest	213800000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7600000	usd
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3400000	usd
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	29981000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	25998000	usd
CY2022Q3	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	27962000	usd
CY2021Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	26841000	usd
CY2022Q3	tvtx	Government Rebates Payable GovernmentRebatesPayable	13366000	usd
CY2021Q4	tvtx	Government Rebates Payable GovernmentRebatesPayable	7493000	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7449000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8402000	usd
CY2022Q3	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	7235000	usd
CY2021Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3144000	usd
CY2022Q3	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	2390000	usd
CY2021Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3302000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	88383000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75180000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63604962	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63604962	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-212659000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-212659000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.34
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64033759	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64033759	shares
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-69656000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-69656000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60803045	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60803045	shares
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-35639000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35639000	usd
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.34
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59230881	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59230881	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-128518000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-128518000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24043806	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17984802	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22751692	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18012120	shares
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	857000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	255000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5018000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6800000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.18
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4064000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5205000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2376000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8826000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6986000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29649000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22190000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1853000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	7297000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7313000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4100000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4100000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12700000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15900000	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares

Files In Submission

Name	View Source	Status
0001438533-22-000051-index-headers.html	Edgar Link	pending
0001438533-22-000051-index.html	Edgar Link	pending
0001438533-22-000051.txt	Edgar Link	pending
0001438533-22-000051-xbrl.zip	Edgar Link	pending
ex09302022311.htm	Edgar Link	pending
ex09302022312.htm	Edgar Link	pending
ex09302022321.htm	Edgar Link	pending
ex09302022322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvtx-20220930.htm	Edgar Link	pending
tvtx-20220930.xsd	Edgar Link	pending
tvtx-20220930_g1.jpg	Edgar Link	pending
tvtx-20220930_cal.xml	Edgar Link	unprocessable
tvtx-20220930_def.xml	Edgar Link	unprocessable
tvtx-20220930_lab.xml	Edgar Link	unprocessable
tvtx-20220930_pre.xml	Edgar Link	unprocessable
tvtx-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2022 Q4 Form 10-Q Financial Statement

#000143853322000051 Filed on October 27, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2022 Q4 Form 10-Q Financial Statement

#000143853322000051 Filed on October 27, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx